For telehealth companies building out men’s health formularies, oral PDE5 inhibitors are the standard first line of treatment for erectile dysfunction. But a clinically significant share of patients does not respond adequately to sildenafil compared to tadalafil and that gap creates a real formulary question.
The trimix injection is the compounded injectable answer. It is a three-component intracavernosal formulation used when oral options fall short, and it represents one of the most clinically established escalation pathways in men’s health.
What Is a Trimix Injection?
A trimix penile injection is administered directly into the corpus cavernosum of the penis. It produces an erection through localized smooth muscle relaxation and increased penile blood flow without requiring systemic absorption or sexual arousal to initiate a response.
The formulation combines three active ingredients: alprostadil, papaverine, and phentolamine. Each compound works through a distinct pharmacological mechanism, and together they act synergistically, which means lower individual doses of each agent can be used in combination than would be required as standalone therapies.
That multi-mechanism approach is the core clinical rationale for the three-compound formulation. Both the American Urological Association (AUA) and the European Association of Urology (EAU) classify intracavernosal injection as second-line therapy for ED, specifically for patients who have not responded adequately to oral PDE5 inhibitors.
The Three Active Ingredients in Compounded Trimix
Understanding the role of each component helps telehealth companies communicate the clinical rationale behind this formulation to their provider networks:
- Alprostadil: A synthetic prostaglandin E1, alprostadil relaxes smooth muscle and dilates penile blood vessels. It is the only FDA-approved standalone injectable agent for erectile dysfunction and serves as the primary driver of the erection response in trimix.
- Papaverine: A non-selective phosphodiesterase inhibitor, papaverine prevents the breakdown of cAMP and cGMP to sustain smooth muscle relaxation. It is not FDA-approved as a standalone ED therapy but is a well-established component in intracavernosal treatment protocols.
- Phentolamine: An alpha-adrenergic blocker, phentolamine supports smooth muscle relaxation by inhibiting norepinephrine-mediated vasoconstriction. Its inclusion at lower concentrations enhances and prolongs the effect of the other two agents.
Compounded Trimix Formulation Strengths
Compounded trimix is not a fixed-ratio product. Each formulation is prepared per individual prescriber specification. This is one of the core advantages of custom compounding over commercial single-agent alternatives.
At Precision Medicine, we offer two standard trimix injection configurations within our formulary:
- 10 mcg / 30 mg / 1 mg (alprostadil / papaverine / phentolamine)
- 20 mcg / 30 mg / 2 mg (alprostadil / papaverine / phentolamine)
Trimix injection dosage is typically guided by ED severity, prior treatment history, and underlying vascular or neurological factors. For telehealth companies, this adjustability is a practical formulary advantage that no fixed commercial product can replicate.
What does the trimix injection site protocol involve?
A trimix injection is executed on the lateral aspect of the penile shaft. Rotation across injection sites is clinically recommended to reduce the risk of tissue damage or fibrosis over time.
Patient education and injection technique training are clinical responsibilities managed at the provider level. Our role is to prepare each trimix penile injection accurately under USP 797-compliant sterile conditions.
Compounded Trimix vs. Commercial Alprostadil
FDA-approved standalone alprostadil (marketed as Caverject and Edex) carries meaningful limitations for telehealth formularies. It is a single-agent product with no formulation flexibility, requires refrigeration, and carries a higher per-dose cost than compounded alternatives.
A study comparing trimix to standalone PGE1 found that the former produced a substantially higher erection response rate across a patient sample with erectile dysfunction. Compounded trimix addresses the single-agent limitation directly.
By combining three agents at lower individual concentrations, the formulation may reduce per-ingredient side effect burden. It may also maintain or improve clinical response.
As a direct to consumer fulfillment provider, we prepare both standard and custom-strength trimix configurations per prescriber order under USP 797-compliant sterile standards. Telehealth companies building sexual health programs should note that compounded trimix is not FDA-approved as a combination product. It is instead fulfilled under 503A compounding guidelines on a per-prescription basis.
Clinical Use Cases for Compounded Trimix
The trimix penile injection is used beyond on-demand ED treatment. It is also a documented option in penile rehabilitation protocols following radical prostatectomy.
Research on long-term ICI satisfaction supports intracavernosal injection as a pathway for patients working to restore erectile function after prostate surgery. Telehealth companies serving urology-adjacent patient populations may find this a relevant use case when expanding their men’s health programming.
Meanwhile, for patients where adjunct therapies (including sermorelin support alongside first-line oral ED medications) have not produced adequate response, the trimix injection is a clinically established escalation pathway. The AUA and EAU both recommend intracavernosal injection as second-line therapy, a designation that directly informs formulary planning decisions for men’s health telehealth companies.
Frequently Asked Questions
How long does a trimix penile injection last?
Duration varies by formulation strength and individual patient response, but erections typically last 30 to 90 minutes. Prescribers generally instruct patients to seek medical attention if an erection persists beyond 4 hours.
What is the trimix injection price?
Cost varies by formulation strength, vial size, and the compounding pharmacy fulfilling the prescription. Because trimix is prepared per prescriber order rather than dispensed as a commercial product, pricing is not standardized. Telehealth companies should confirm pricing directly with their fulfillment pharmacy partner.
What are the trimix injection side effects?
The most commonly reported effects include pain or bruising at the injection site, prolonged erection (priapism), and fibrosis with long-term use. Because trimix uses lower concentrations of each active ingredient than single-agent therapy, some practitioners consider it better tolerated than standalone alprostadil. Adverse event monitoring is managed at the prescriber level.
Is trimix stronger than oral ED medications?
Trimix operates through a different mechanism than oral PDE5 inhibitors and is indicated when oral options have not produced adequate response. Comparative efficacy depends on the underlying etiology of ED and individual patient physiology. It is not accurate to characterize one approach as universally stronger than the other.
Can compounded trimix be stored at room temperature?
Compounded trimix requires refrigeration to maintain stability. Patients should follow the storage instructions provided by the dispensing pharmacy and should not use the medication beyond its beyond-use date.
When First-Line ED Treatment Isn’t Enough
Compounded trimix brings together three pharmacologically distinct agents in a single adjustable formulation with variable strength ratios that allow prescribers to titrate response based on individual patient needs. At Precision Medicine, our role as a compounding pharmacy is to prepare the formulation accurately per prescriber specification under USP 797 sterile standards.
Clinical decisions, dosing protocols, and adverse event management remain entirely within the provider’s scope.
Telehealth companies building or expanding their men’s health programs can reference our formulary for standard trimix configurations. You can also connect with our team to explore fulfillment capabilities across both sterile and non-sterile compounded therapies.